10070 Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices 

Johnson Matthey Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Johnson Matthey Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: February 15, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3925 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated October 8, 2010, and 

published in the Federal Register on 

October 20, 2010, 75 FR 64745, Halo 

Pharmaceutical Inc., 30 North Jefferson 

Road, Whippany, New Jersey 07981, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Hydromorphone (9150) ................ II 

Dihydromorphine is an intermediate 

in the manufacture of Hydromorphone 

and is not for commercial distribution. 

The company plans to manufacture 

Hydromorphone HCL for sale to other 

manufacturers and for the manufacture 

of other controlled substance dosage 

units for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of Halo 

Pharmaceutical Inc. to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Halo Pharmaceutical Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: February 16, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–3924 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Parole Commission 

[5 U.S.C. Section 552b] 

Meetings; Sunshine Act; Public 

Announcement Pursuant to the 

Government in the Sunshine Act 

Public Law 94–409 

AGENCY HOLDING MEETING: Department of 

Justice, United States Parole 

Commission. 

DATE AND TIME: 10 a.m., Thursday, 

February 17, 2011. 

PLACE: U.S. Parole Commission, 5550 

Friendship Boulevard, 4th Floor, Chevy 

Chase, Maryland 20815. 

STATUS: Closed. 

MATTERS CONSIDERED: The following 

matter will be considered during the 

closed meeting: Discussion of an 

original jurisdiction case pursuant to 28 

CFR 2.17. 

AGENCY CONTACT: Patricia W. Moore, 

Staff Assistant to the Chairman, United 

States Parole Commission, (301) 492– 

5933. 

Dated: February 15, 2011, 

Rockne Chickinell, 

General Counsel, U.S. Parole Commission. 

[FR Doc. 2011–3902 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–31–M 

DEPARTMENT OF JUSTICE 

United States Parole Commission 

Record of Vote of Meeting Closure 

(Pub. L. 94–409) (5 U.S.C. Sec. 552b) 

I, Isaac Fulwood, of the United States 

Parole Commission, was present at a 

meeting of said Commission, which 

started at approximately 11:30 a.m., on 

Thursday, February 10, 2011, at the U.S. 

Parole Commission, 5550 Friendship 

Boulevard, 4th Floor, Chevy Chase, 

Maryland 20815. The purpose of the 

meeting was to decide four petitions for 

reconsideration pursuant to 28 CFR 

Section 2.27 and one pursuant to 28 

CFR Section 2.17. Four Commissioners 

were present, constituting a quorum 

when the vote to close the meeting was 

submitted. 

Public announcement further 

describing the subject matter of the 

meeting and certifications of General 

Counsel that this meeting may be closed 

by vote of the Commissioners present 

were submitted to the Commissioners 

prior to the conduct of any other 

business. Upon motion duly made, 

seconded, and carried, the following 

Commissioners voted that the meeting 

be closed: Isaac Fulwood, Cranston J. 

Mitchell, Patricia Cushwa and J. Patricia 

Wilson Smoot. 

In witness whereof, I make this official 

record of the vote taken to close this 

meeting and authorize this record to be 

made available to the public. 

Dated: February 11, 2011. 

Isaac Fulwood, 

Chairman, U.S. Parole Commission. 

[FR Doc. 2011–3891 Filed 2–22–11; 8:45 am] 

BILLING CODE 4410–01–M 

DEPARTMENT OF LABOR 

Office of Workers’ Compensation 

Programs 

Division of Coal Mine Workers’ 

Compensation; Proposed Extension of 

Existing Collection; Comment Request 

ACTION: Notice. 

SUMMARY: The Department of Labor, as 

part of its continuing effort to reduce 

paperwork and respondent burden, 

conducts a pre-clearance consultation 

program to provide the general public 

and Federal agencies with an 

opportunity to comment on proposed 

and/or continuing collections of 

information in accordance with the 

Paperwork Reduction Act of 1995 

(PRA95) [44 U.S.C. 3506(c)(2)(A)]. This 

program helps to ensure that requested 

data can be provided in the desired 

format, reporting burden (time and 

financial resources) is minimized, 

collection instruments are clearly 

understood, and the impact of collection 

requirements on respondents can be 

properly assessed. Currently, the Office 

of Workers’ Compensation Programs is 

soliciting comments concerning its 

proposal to extend OMB approval of the 

information collection for the following 

medical reports: 

mstockstill on DSKH9S0YB1PROD with NOTICES